Business

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, ABBV, MGTI and JT

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, ABBV, MGTI and JT.

articleMgt Capital Investments, Inc.November 7, 20184/company/mgt-capital-investments-inc/news/the-klein-law-firm-reminds-investors-of-class-actions-on-behalf-of-shareholders-of-usat-abbv-mgti-and-jt
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, ABBV, MGTI and JT

About this update from Mgt Capital Investments, Inc.

[{"type":"text","content":"\nNEW YORK, Nov. 07, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.      \n USA Technologies, Inc. (NASDAQGM: USAT) Class Period: November 9, 2017 to September 11, 2018 Lead Plaintiff Deadline: November 13, 2018 Throughout the class period, USA Technologies, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) USA Technologies’ treatment of contractual arrangements in its financial statements would result in an internal investigation and delay the filing of its annual report for fiscal year 2018; (2) consequently, USA Technologies’ internal controls over financial reporting were weak and deficient; (3) as a result, defendants’ statements about USA Technologies’ business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Get additional information about the USAT lawsuit: http://www.kleinstocklaw.com/pslra-1/usa-technologies-inc-loss-submission-form?wire=3 AbbVie Inc. (NYSE: ABBV) Class Period: October 25, 2013 to September 18, 2018 Lead Plaintiff Deadline: November 20, 2018 The lawsuit alleges that AbbVie Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, relied in part upon illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would foreseeably lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Get additional information about the ABBV lawsuit: http://www.kleinstocklaw.com/pslra-1/abbvie-inc-loss-submission-form?wire=3 MGT Capital Investments Inc. (OTCMKTS: MGTI) Class Period: October 9, 2015 to September 7, 2018 Lead Plaintiff Deadline: November 27, 2018 The complaint alleges that during the class period MGT Capital Investments Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants were engaged in an illegal pump-and-dump ...

More updates from Mgt Capital Investments, Inc.